Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Annamycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Moleculin Confirms Annamycin's Safety On Heart In 90-Person Study
    Moleculin Confirms Annamycin's Safety On Heart In 90-Person Study

    13 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/13/3217831/0/en/Moleculin-Reports-Independent-Assessment-Confirms-No-Cardiotoxicity-of-Annamycin-in-90-Subjects.html

    GLOBENEWSWIRE
    13 Jan 2026
    Share Share
    Moleculin Accelerates 2026 Outlook with Global Pivotal Unblinding
    Moleculin Accelerates 2026 Outlook with Global Pivotal Unblinding

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216928/0/en/Moleculin-Accelerates-Outlook-Into-2026-With-First-Pivotal-Trial-Unblinding-on-Track-Global-Trial-Expansion-and-Multiple-Externally-IIT-Funded-Clinical-Programs.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Moleculin Completes Dosing 45 Patients in MIRACLE AML Trial
    Moleculin Completes Dosing 45 Patients in MIRACLE AML Trial

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202323/0/en/Moleculin-Announces-Completion-of-Treatment-for-the-45-Patients-in-Pivotal-MIRACLE-Phase-3-AML-Trial-on-Pace-for-Q1-2026.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    Moleculin Announces New Annamycin Collaboration in Brain Tumors
    Moleculin Announces New Annamycin Collaboration in Brain Tumors

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201521/0/en/Moleculin-Announces-New-Annamycin-Collaboration-in-Brain-Tumors.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Moleculin Reaches 60% Consent in MIRACLE AML Trial
    Moleculin Reaches 60% Consent in MIRACLE AML Trial

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187380/0/en/Moleculin-Reports-60-of-First-45-Subjects-in-Pivotal-MIRACLE-Phase-3-AML-Trial-Consented.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share
    Moleculin Announces Grant Funded Research Evaluating Annamycin
    Moleculin Announces Grant Funded Research Evaluating Annamycin

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186289/0/en/Moleculin-Announces-Grant-Funded-Research-Evaluating-Annamycin-for-the-Treatment-of-Pancreatic-Cancer-at-UNC-Chapel-Hill.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.